Fortress Biotech, Inc. (FBIO)
2.03
-0.04
(-1.93%)
USD |
NASDAQ |
Oct 02, 16:00
2.035
0.00 (0.00%)
After-Hours: 20:00
Fortress Biotech Enterprise Value : -33.69M for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | -33.69M |
| October 01, 2026 | -32.36M |
| September 30, 2026 | -30.03M |
| September 29, 2026 | -28.03M |
| September 28, 2026 | -29.03M |
| September 25, 2026 | -25.36M |
| September 24, 2026 | -25.36M |
| September 23, 2026 | -23.36M |
| September 22, 2026 | -19.70M |
| September 21, 2026 | -21.03M |
| September 18, 2026 | -17.70M |
| September 17, 2026 | -17.70M |
| September 16, 2026 | -19.37M |
| September 15, 2026 | -18.37M |
| September 14, 2026 | -17.03M |
| September 11, 2026 | -17.37M |
| September 10, 2026 | -15.70M |
| September 09, 2026 | -13.70M |
| September 08, 2026 | -11.04M |
| September 04, 2026 | -10.71M |
| September 03, 2026 | -11.04M |
| September 02, 2026 | -10.37M |
| September 01, 2026 | -12.04M |
| August 31, 2026 | -10.21M |
| August 28, 2026 | -9.040M |
| Date | Value |
|---|---|
| August 27, 2026 | -8.040M |
| August 26, 2026 | -7.707M |
| August 25, 2026 | -7.041M |
| August 24, 2026 | -3.710M |
| August 21, 2026 | -5.708M |
| August 20, 2026 | -9.040M |
| August 19, 2026 | -6.375M |
| August 18, 2026 | -4.376M |
| August 17, 2026 | -7.374M |
| August 14, 2026 | -3.710M |
| August 13, 2026 | -2.044M |
| August 12, 2026 | -9.706M |
| August 11, 2026 | -14.37M |
| August 10, 2026 | -9.706M |
| August 07, 2026 | -12.37M |
| August 06, 2026 | -9.040M |
| August 05, 2026 | -8.373M |
| August 04, 2026 | -10.71M |
| August 03, 2026 | -9.373M |
| July 31, 2026 | 2.952M |
| July 30, 2026 | 8.282M |
| July 29, 2026 | 10.28M |
| July 28, 2026 | 11.61M |
| July 27, 2026 | 7.616M |
| July 24, 2026 | 9.948M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Inovio Pharmaceuticals, Inc. | 66.84M |
| Kura Oncology, Inc. | 452.79M |
| Spero Therapeutics, Inc. | 20.46M |
| ACADIA Pharmaceuticals, Inc. | 2.551B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 0.602M |
| Revenue (Quarterly) | 18.72M |
| Total Expenses (Quarterly) | 19.19M |
| EPS Diluted (Quarterly) | -0.0779 |
| Gross Profit Margin (Quarterly) | 61.50% |
| Profit Margin (Quarterly) | 3.22% |
| Earnings Yield | 130.9% |
| Normalized Earnings Yield | 120.63 |